Nonsteroidal anti-inflammatory drug-induced hepatoxicity

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 643-656

  Unzueta, Alberto ^a   Vargas, Hugo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute liver injury; Drug safety; Drug surveillance; Drug induced liver injury; Hy's law; Idiosyncratic hepatotoxicity; Liver transplantation; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; BENOXAPROFEN; BILIRUBIN; BROMFENAC; CELECOXIB; DICLOFENAC; ETORICOXIB; HLA DQA1 ANTIGEN; IBUFENAC; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC;

ABDOMINAL PAIN; ALCOHOL ABUSE; AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; COMORBIDITY; CROSS REACTION; DISEASE SEVERITY; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG RECALL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HUMAN; KIDNEY DISEASE; LIVER CELL DAMAGE; LIVER TOXICITY; LIVER TRANSPLANTATION; NAUSEA; OBSTRUCTIVE JAUNDICE; OSTEOARTHRITIS; POSTMARKETING SURVEILLANCE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; REYE SYNDROME; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); TOXIC HEPATITIS; VOMITING;

ACUTE LIVER INJURY; DRUG SAFETY; DRUG SURVEILLANCE; DRUG-INDUCED LIVER INJURY; HY'S LAW; IDIOSYNCRATIC HEPATOTOXICITY; LIVER TRANSPLANTATION; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG-INDUCED LIVER INJURY; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84884970156     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.009     Document Type: Review

References (87)

1. Lee W.M., Squires R.H., Nyberg S.L., et al. Acute liver failure: summary of a workshop. Hepatology 2008, 47(4):1401-1415.
2. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. NEngl J Med 2006, 354(7):731-739.
3. Bjornsson E., Jerlstad P., Bergqvist A., et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005, 40(9):1095-1101.
4. Russo M.W., Galanko J.A., Shrestha R., et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004, 10(8):1018-1023.
5. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129(2):512-521.
6. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135(6):1924-1934.
7. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36(2):451-455.
8. Carey E.J., Vargas H.E., Douglas D.D., et al. Inpatient admissions for drug-induced liver injury: results from a single center. Dig Dis Sci 2008, 53(7):1977-1982.
9. Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011, 89(6):806-815.
10. Zimmerman H. Drug-induced liver disease. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver 1978, 353. Appleton-Century-Crofts, New York. 1st edition.
11. Reuben A. Hy's law. Hepatology 2004, 39(2):574-578.
12. Senior J.R. How can 'Hy's law' help the clinician?. Pharmacoepidemiol Drug Saf 2006, 15(4):235-239.
13. Bjornsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005, 42(2):481-489.
14. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006, 15(4):241-243.
15. Danan G., Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. JClin Epidemiol 1993, 46(11):1323-1330.
16. Suzuki A., Andrade R.J., Bjornsson E., et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in vigibase: unified list based on international collaborative work. Drug Saf 2010, 33(6):503-522.
17. Hunter E.B., Johnston P.E., Tanner G., et al. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol 1999, 94(8):2299-2301.
18. Rabkin J.M., Smith M.J., Orloff S.L., et al. Fatal fulminant hepatitis associated with bromfenac use. Ann Pharmacother 1999, 33(9):945-947.
19. Moses P.L., Schroeder B., Alkhatib O., et al. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 1999, 94(5):1393-1396.
20. Fontana R.J., McCashland T.M., Benner K.G., et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg 1999, 5(6):480-484.
21. Goldkind L., Laine L. Asystematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 2006, 15(4):213-220.
22. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005, 4(6):489-499.
23. Lee W.M. Drug-induced hepatotoxicity. NEngl J Med 2003, 349(5):474-485.
24. Kaplowitz N. Avoiding hepatic injury from drugs. Gastroenterology 1999, 117(4):759.
25. Duthie A., Nicholls A., Freeth M., et al. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br Med J (Clin Res Ed) 1982, 285(6334):62.
26. Taggart H.M., Alderdice J.M. Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br Med J (Clin Res Ed) 1982, 284(6326):1372.
27. Lewis J.H. Nonsteroidal anti-inflammatory drugs and leukotriene receptor antagonists: pathology and clinical presentation of hepatotoxicity. Drug-induced liver disease 2007, 439-464. Informa Healthcare USA, New York. 2nd edition. N. Kaplowitz, L.D. DeLeve (Eds.).
28. Chitturi S., Farrell G.C. Identifying who is at risk of drug-induced liver injury: is human leukocyte antigen specificity the key?. Hepatology 2011, 53(1):358-362.
29. Farkouh M.E., Kirshner H., Harrington R.A., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004, 364(9435):675-684.
30. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004, 364(9435):665-674.
31. Chitturi S., Farrell G.C. Lessons from Lumiracoxib: are cyclooxygenase-2 inhibitors less hepatotoxic than non-selective non-steroidal anti-inflammatory drugs?. JGastroenterol Hepatol 2012, 27(6):993-994.
32. Pillans P.I., Ghiculescu R.A., Lampe G., et al. Severe acute liver injury associated with lumiracoxib. JGastroenterol Hepatol 2012, 27(6):1102-1105.
33. Singer J.B., Lewitzky S., Leroy E., et al. Agenome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nature 2010, 42(8):711-714.
34. Russmann S., Jetter A., Kullak-Ublick G.A. Pharmacogenetics of drug-induced liver injury. Hepatology 2010, 52(2):748-761.
35. Riley T.R., Smith J.P. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 1998, 93(9):1563-1565.
36. Bessone F., Colombato L., Fassio E., et al. The spectrum of nimesulide-induced-hepatotoxicity. An overview. Antiinflamm Antiallergy Agents Med Chem 2010, 9(4):355-365.
37. Walker S.L., Kennedy F., Niamh N., et al. Nimesulide associated fulminant hepatic failure. Pharmacoepidemiol Drug Saf 2008, 17(11):1108-1112.
38. Venegoni M., Da Cas R., Menniti-Ippolito F., et al. Effects of the European restrictive actions concerning nimesulide prescription: a simulation study on hepatopathies and gastrointestinal bleedings in Italy. Ann Ist Super Sanita 2010, 46(2):153-157.
39. Traversa G., Bianchi C., Da Cas R., et al. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003, 327(7405):18-22.
40. Rainsford K.D. Members of the Consensus Report Group on N. Nimesulide: a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006, 22(6):1161-1170.
41. European Medicines Agency concludes review of systemic nimesulide-containing medicines. 2011. Available at:. http://www.ema.europa.eu/ema/index.jsp?curl%3Dpages/medicines/human/referrals/Nimesulide/human_referral_000275.jsp%26mid%3DWC0b01ac0580024e99%26murl%3Dmenus/regulations/regulations.jsp.
42. Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage?. World J Gastroenterol 2010, 16(45):5651-5661.
43. Laine L., Goldkind L., Curtis S.P., et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 2009, 104(2):356-362.
44. Lee C.H., Wang J.D., Chen P.C. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf 2010, 19(7):708-714.
45. Sanchez-Matienzo D., Arana A., Castellsague J., et al. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther 2006, 28(8):1123-1132.
46. Lapeyre-Mestre M., de Castro A.M., Bareille M.P., et al. Non-steroidal antiinflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 2006, 20(4):391-395.
47. Rubenstein J.H., Laine L. Systematic review: the hepatotoxicity of nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004, 20(4):373-380.
48. Rostom A., Goldkind L., Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005, 3(5):489-498.
49. Garcia Rodriguez L.A., Williams R., Derby L.E., et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994, 154(3):311-316.
50. Chalasani N., Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010, 138(7):2246-2259.
51. Licata A., Calvaruso V., Cappello M., et al. Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. Dig Liver Dis 2010, 42(2):143-148.
52. Daly A.K., Aithal G.P., Leathart J.B., et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007, 132(1):272-281.
53. Zimmerman H.J. Update of hepatotoxicity due to classes of drugs in commonclinical use: nonsteroidal drugs, antiinflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin Liver Dis 1990, 10(4):322-328.
54. Alam I., Ferrell L.D., Bass N.M. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol 1996, 91(8):1626-1630.
55. Srivastava M., Perez-Atayde A., Jonas M.M. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology 1998, 115(3):743-746.
56. Andrade R.J., Lucena M.I., Garcia-Cortes M., et al. Chronic hepatitis C, ibuprofen, and liver damage. Am J Gastroenterol 2002, 97(7):1854-1855.
57. Bjornsson E., Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006, 38(1):33-38.
58. Agundez J.A., Lucena M.I., Martinez C., et al. Assessment of nonsteroidal antiinflammatory drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2011, 7(7):817-828.
59. Walker A.M. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum 1997, 40(2):201-208.
60. Manoukian A.V., Carson J.L. Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf 1996, 15(1):64-71.
61. Andrejak M., Davion T., Gineston J.L., et al. Cross hepatotoxicity between nonsteroidal anti-inflammatory drugs. Br Med J (Clin Res Ed) 1987, 295(6591):180-181.
62. Demirag M.D., Ozenirler S., Goker B., et al. Idiosyncratic toxic hepatitis secondary to single dose of naproxen. Acta Gastroenterol Belg 2007, 70(2):247-248.
63. Fredell E.W., Strand L.J. Naproxen overdose. JAMA 1977, 238(9):938.
64. Arellano F.M., Yood M.U., Wentworth C.E., et al. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf 2006, 15(12):861-872.
65. Zimmerman H. Drugs used to treat rheumatic and musculospastic disease. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver 1999, 599-602. Lippincott Williams & Williams, Philadelphia. 2nd edition. H. Zimmerman (Ed.).
66. Scully L.J., Clarke D., Barr R.J. Diclofenac induced hepatitis: 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993, 38(4):744-751.
67. Banks A.T., Zimmerman H.J., Ishak K.G., et al. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food-and-Drug-Administration as adverse reactions. Hepatology 1995, 22(3):820-827.
68. de Abajo F.J., Montero D., Madurga M., et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004, 58(1):71-80.
69. Boelsterli U.A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003, 192(3):307-322.
70. Aithal G.P., Ramsay L., Daly A.K., et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004, 39(5):1430-1440.
71. Aithal G.P. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Expert Opin Drug Saf 2004, 3(6):519-523.
72. Tarazi E.M., Harter J.G., Zimmerman H.J., et al. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993, 104(2):569-574.
73. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. NEngl J Med 1993, 328(18):1313-1316.
74. Guldenschuh I., Hurlimann R., Muller A., et al. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis: reply. Dis Colon Rectum 2001, 44(8):1098-1099.
75. Brogden R.N., Heel R.C., Speight T.M., et al. Piroxicam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1981, 22(3):165-187.
76. Lee S.M., O'Brien C.J., Williams R., et al. Subacute hepatic necrosis induced by piroxicam. Br Med J (Clin Res Ed) 1986, 293(6546):540-541.
77. Planas R., De Leon R., Quer J.C., et al. Fatal submassive necrosis of the liver associated with piroxicam. Am J Gastroenterol 1990, 85(4):468-470.
78. Paterson D., Kerlin P., Walker N., et al. Piroxicam induced submassive necrosis of the liver. Gut 1992, 33(10):1436-1438.
79. Hepps K.S., Maliha G.M., Estrada R., et al. Severe cholestatic jaundice associated with piroxicam. Gastroenterology 1991, 101(6):1737-1740.
80. Caballeria E., Masso R.M., Arago J.V., et al. Piroxicam hepatotoxicity. Am J Gastroenterol 1990, 85(7):898-899.
81. Laine L., White W.B., Rostom A., et al. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008, 38(3):165-187.
82. Maddrey W.C., Maurath C.J., Verburg K.M., et al. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 2000, 7(3):153-158.
83. Soni P., Shell B., Cawkwell G., et al. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Curr Med Res Opin 2009, 25(8):1841-1851.
84. El Hajj I.I., Malik S.M., Alwakeel H.R., et al. Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation. World J Gastroenterol 2009, 15(31):3937-3939.
85. Nachimuthu S., Volfinzon L., Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J 2001, 77(910):548-550.
86. Zimmerman H.J. Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981, 141(3 Spec No):333-342.
87. Belay E.D., Bresee J.S., Holman R.C., et al. Reye's syndrome in the United States from 1981 through 1997. NEngl J Med 1999, 340(18):1377-1382.